Safety of the intervention (adverse effects) · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
1 finding from 1 review
Total number of oral ulcers · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
Colchicine (systemic; 0.5 mg weight-adjusted daily) showed no clear difference in total number of oral ulcers compared with placebo (moderate certainty).
1 finding from 1 review
Time to complete healing · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
Sucralfate suspension (topical) showed no clear difference in healing time compared with placebo suspension; GRADE not reported.
1 finding from 1 review
Number of episodes · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
Sucralfate suspension (topical) showed no clear difference in number of episodes compared with placebo suspension; GRADE not reported.
1 finding from 1 review
Pain (0-3 scale) · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
Sucralfate suspension (topical) showed no clear difference in pain (0-3 scale) compared with placebo suspension; GRADE not reported.
1 finding from 1 review
Total number of oral ulcers · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
Interferon-alpha (topical; hydrogel or lozenges) showed no clear difference in total number of oral ulcers compared with placebo; GRADE not reported.
1 finding from 1 review
Safety of the intervention (adverse effects) · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
1 finding from 1 review
Global aphthae count and pain score · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
1 finding from 1 review
Matsuda 2003 (rebamipide 300 mg daily vs placebo, 35 patients; high risk of reporting bias; concomitant treatments): authors stated that rebamipide improved the global evaluation aphthae count and global evaluation…
1 study · 35 participants
GRADE not reported
Total ulcer burden · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
1 finding from 1 review
Interventions for managing oral ulcers in Behçet's disease 2014 · Cochrane All outcomesInterferon-alpha dose comparison
Kilic 2009 (interferon-alpha 1000 IU vs 2000 IU lozenges, 84 patients): the data presented did not allow analysis; authors reported no statistically significant difference in total ulcer burden between the two doses.
1 study · 84 participants
GRADE not reported
Safety of the intervention (adverse effects) · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
1 finding from 1 review
Hamuryudan 1998: significant adverse effects including severe sedation, polyneuropathy, loss of libido, and weight gain; a greater number of adverse events was seen for the higher (300 mg) dose; 4 patients withdrew due…
1 study · 101 participants
GRADE not reported
Number of painful days · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
Sucralfate suspension (topical) showed no clear difference in number of painful days compared with placebo suspension; GRADE not reported.
1 finding from 1 review
Number of (minor aphthous) oral ulcers · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
1 finding from 1 review
Hamuryudan 1998 (thalidomide 100 mg or 300 mg daily vs placebo, 101 male patients; high risk of reporting bias): a significant effect on mean numbers of minor oral ulcers was reported from week 4 in both thalidomide…
1 study · 101 participants
GRADE not reported
Oral ulcers (number, size, healing time) · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
1 finding from 1 review
Ergun 1997 (cyclosporin A in orabase vs placebo orabase, 24 patients; high risk of reporting bias): no data were presented; authors reported no clinical improvement in the number, size, and healing time of ulcers for…
1 study · 24 participants
GRADE not reported
Safety of the intervention (adverse effects) · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
1 finding from 1 review
Alpsoy 2002: high rate of adverse events including alopecia, leukopenia, and diarrhoea; 18 of 23 patients in the treatment arm experienced mild flu-like symptoms.
1 study · 50 participants
GRADE not reported
Episode frequency associated with oral ulcers · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
Sucralfate suspension (topical) showed no clear difference in frequency of oral ulcers compared with placebo suspension; GRADE not reported.
1 finding from 1 review
Improvement in burning mouth symptoms · Adults over 18 years of age with chronic orofacial pain (burning mouth syndrome)
Cognitive behavioural (group psychotherapy) therapy showed no clear difference in improvement in burning mouth symptoms compared with placebo pill; GRADE not reported.
1 finding from 1 review
RR 1.77 [0.98, 3.21]
1 study
GRADE not reported
Life interference · Adults over 18 years of age with chronic orofacial pain (temporomandibular disorder (TMD))
Habit reversal showed no clear difference in life interference compared with waiting list control; GRADE not reported.
1 finding from 1 review
SMD -0.86 [-1.79, 0.06]
1 study
GRADE not reported
Reduction in pain intensity · Adults over 18 years of age with chronic orofacial pain (temporomandibular disorder (TMD))
Hypnosis led to lower pain intensity (short term) compared with relaxation; GRADE not reported.
1 finding from 1 review
Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · Adults over 18 years of age with chronic orofacial pain (temporomandibular disorder (TMD))
Habit reversal led to lower pain intensity (short term / post-treatment) compared with waiting list control; GRADE not reported.
1 finding from 1 review
SMD -1.31 [-1.97, -0.65]
1 study
GRADE not reported
Depression (short term) · Adults over 18 years of age with chronic orofacial pain (temporomandibular disorder (TMD))
Hypnosis led to lower depression (short term) compared with relaxation; GRADE not reported.
1 finding from 1 review